Background: Heme oxygenase-1 (HO-1) is an endogenous anti-stress enzyme that catabolizes heme to free iron, carbon monoxide (CO), and biliverdin. Recently, CO is postulated to play a protective role against tissue injury induced by several stresses. In this study, we investigated the role of CO in amelioration of cardiac ischemia-reperfusion injury, and the mechanism involved in it. Methods and Results: Rats inhaled CO (250 ppm, 500 ppm, or 1000 ppm, balanced with air) or room air for 24 hr in a chamber. Then the left anterior descending coronary artery was occluded for 30 min, followed by 120 min reperfusion, during which they continued inhaling CO or room air. CO had no effects on body temperature or hemodynamic parameters before ischemia-reperfusion. Pretreatment with 1000 ppm of CO, but not 250 ppm nor 500 ppm, significantly reduced the ratio of the infarct area to the risk area (I/R ratio; room air 35 ± 4 % vs. 1000 ppm CO 6 ± 2 %, P < 0.001), and suppressed the migration of macrophages and monocytes, and the expression of tumor necrosis factor-a (TNF-a) in the risk areas (P < 0.05, those with 1000 ppm CO vs. without CO). Inhalation of 1000 ppm CO elevated HbCO up to 30% in blood. Thus, tissue hypoxia-induced preconditioning is suspected to be responsible for this phenomenon. However, the simple hypoxia (under 0.5 atom air for 24 hr) did not reduce I/R ratio. CO activated MAPKs (p38, JNK, and ERK), Akt, and eNOS in the heart within 12 hours; although neither 250 ppm nor 500 ppm CO nor exposure to the simple hypoxia activated them. Pre-treatment with SB203580, or wormannin completely blocked the activation of p38, or Akt and eNOS, respectively. They disturbed the cytoprotective effects of CO additively (I/R ratio; 20 ± 3% (SB203580 + CO), 23 ± 2 % (wortmannin + CO), and 39 ± 4 % (SB203580 + wortmannin + CO) vs. those with vehicle + CO; 9 ± 3 %, respectively, P < 0.05). L-NAME (an inhibitor of NO production) also attenuated the tissue protection by CO to almost to the same level as wortmannin (I/R ratio; 22 ± 5 % (L-NAME+CO)). Conclusion: CO protects heart from ischemia-reperfusion injury. P38 pathway and AkteNOS pathway are the key pathways in the cytoprotective effect of CO. The inactive form of B-type Natriuretic Peptide, NT-proBNP, is a marker of acute as well of chronic cardiac dysfunction. NT-proBNP is markedly elevated in acute nonSTE-ACS and elevated levels are associated with an increased short-and long-term mortality. However, little is known about the temporal changes of NT-proBNP and their causes after an episode of nonSTE-ACS. Methods: NT-proBNP was measured at inclusion in the study, after 6 weeks, 3 and 6 months together with Troponin T and C-Reactive Protein at inclusion in 642 patients included in the FRISC-II invasive trial. The association between changes of NT-proBNP over time and a number of clinical and laboratory parameters was evaluated by multiple linear regression analysis.
884-2 Cardiac Dysfunction in Non-ST Elevation ACS Is Partly Reversible: Analysis of Serial Measurements of NT-Pro B-Type Natriutetic Peptide
Bertil Lindahl, Nina Johnston, Tomas Jernberg, Matts Stridsberg, Per Venge, Lars Wallentin, The FRISK-II Study Group, University Hospital, Uppsala, Sweden
The inactive form of B-type Natriuretic Peptide, NT-proBNP, is a marker of acute as well of chronic cardiac dysfunction. NT-proBNP is markedly elevated in acute nonSTE-ACS and elevated levels are associated with an increased short-and long-term mortality. However, little is known about the temporal changes of NT-proBNP and their causes after an episode of nonSTE-ACS. Methods: NT-proBNP was measured at inclusion in the study, after 6 weeks, 3 and 6 months together with Troponin T and C-Reactive Protein at inclusion in 642 patients included in the FRISC-II invasive trial. The association between changes of NT-proBNP over time and a number of clinical and laboratory parameters was evaluated by multiple linear regression analysis.
Results:
The NT-proBNP level decreased in median 172 ng/L (25 th -75 th perc.; 2-671) from inclusion to 6 months. There was no significant statistically change in patients without any myocardial damage (tnT <0.01 µg/L). In patients with myocardial damage (tnT >0.01 µg/L) higher levels of tnT and CRP were associated with a larger decrease in NTproBNP, whereas higher weight, a history of diabetes, smoking and chronic heart failure, respectively, were associated with increasing NT-proBNP levels. Conclusion: Cardiac dysfunction, as measured by NT-proBNP, is to a large extent reversible in nonSTE-ACS patients. Reversible dysfunction is associated with tnT and CRP elevation. Irreversible dysfunction is associated with diabetes, chronic heart failure, smoking and weight.
11:00 a.m. Background: Myocardial ischemia is associated with increased arterial stiffness which causes early return of reflected pressure waves from the lower body and augments aortic systolic and pulse pressures and increases left ventricular afterload and myocardial oxygen demand. The aim of this study was to determine if arterial properties and wave reflection characteristics are altered after EECP treatment in patients with chronic stable angina resistant to anti-anginal medication. Methods: High-fidelity radial artery pressure waveforms were recorded non-invasively by applanation tonometry and ascending aortic pressure waveforms generated using a mathematical transfer function. Twenty patients (age 61±7.3 years) with refractory angina taking two or more anti-anginal drugs were studied. Data were collected before and after 34 one-hour EECP sessions. Augmentation index (AIa, index of aortic stiffness) and amplitude and timing of the reflected pressure wave (index of myocardial oxygen demand) were calculated from the generated aortic pressure waveform. Results: EECP caused a significant decline in AIa from 27±10 to 19±9.8% (p<0.02) and a delay in reflected wave travel time from 68±8.3 to 74±6.8 msec (p<0.01). These modifications in wave reflection characteristics were associated with a decline in reflected wave amplitude (from 13±7.2 to 9.0±7.0 mm Hg, p<0.01) and duration (from 189±34 to 174±40 msec, p<0.01) which caused a decrease in aortic systolic (from 120±18 to 108±18 mm Hg, p<0.01) and pulse (from 48±15 to 41±16 mm Hg,p<0.01) pressure. The average number of anginal episodes per week decreased from 7.1±6.0 to 1.1±1.2 (p<0.02) while heart rate, body weight and drug regimen did not change during the course of the study. Conclusions: EECP treatment delays return of the reflected pressure wave from the periphery to the heart, reduces its amplitude and, therefore, decreases aortic blood pressure and systolic stress in patients with refractory angina taking anti-anginal medication. These changes, which are likely due to decreased arterial stiffness and pulse wave velocity of the muscular arteries in the legs, reduce myocardial oxygen demand and decrease the number of anginal episodes.
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891-2 External Counterpulsation Therapy: Significant Clinical Improvement Without Electrophysiologic Remodeling
Charles A. Henrikson, Nisha Chandra-Strobos, Johns Hopkins Medical Institutions, Baltimore, MD Background: External counterpulsation therapy (ECP) non-invasively improves coronary flow, hemodynamics, and time to ischemia in patients with severe coronary artery disease (CAD). Other treatments with similar effects, e.g. left ventricular assist devices, promote electrophysiologic remodeling, with a narrowing of the QRS complex. Methods: We studied 28 patients, who completed a 7 week 35 hour session of ECP, to assess whether such therapy would also result in electrophysiological remodeling, especially if associated with clinical improvement. All patients had class II-III angina, imagingproven ischemia, and severe CAD. Results: Of 28 patients, with mean age 62+/-13 years (mean +/-SD), 78% were male, 46% diabetic, 82% hypertensive, 60% had undergone angioplasty, and 67% bypass surgery. The mean ejection fraction was 44% (range 25-60%). Following ECP, most patients (82%) had at least a one full class improvement in their anginal pattern. In most patients, there was substantial baseline conduction system disease present: a mean QRS of 105 +/-19 msec. Of note, there was no significant change in heart rate, PR, QRS, or QTc intervals before and after ECP in either clinical responders or non-responders. When High strain spots 0.7 ± 0.5 1.7 ± 0.4 2.0 ± 0.8
